Syntaxin-5 (STX5)

Syntaxin-5 (STX5) is a member of the syntaxin family within the SNARE (soluble NSF attachment protein receptor) class of proteins, which mediate membrane fusion during intracellular vesicular transport[3][4]. It exists as two main isoforms: a long form (~42 kDa) that localizes to both the endoplasmic reticulum (ER) and Golgi, and a short form (~35 kDa) principally in the Golgi complex[1][2]. Syntaxin-5 is essential for vesicle tethering and fusion at the cis-Golgi membrane, and for the transport of materials from the ER to the Golgi[4][2]. The long form also plays a structural role in organizing the ER by interacting with microtubules and the ER membrane protein CLIMP-63, independently of its SNARE-mediated fusion function[1][2]. STX5 dysfunction has been linked to congenital disorders of glycosylation (notably CDG2AA) and is involved in key processes such as Golgi assembly, lipid droplet fusion, endosome-to-Golgi transport, and possibly neurological conditions such as Alzheimer's disease[2]. To date, there are no documented drugs that specifically target syntaxin-5, nor established therapeutic mechanisms, biomarkers, or safety concerns in drug targeting for this protein.

Other names

STX5ASED5CDG2AAsyntaxin-5syntaxin 5ASED5p